Abstract
目的了解原发胃肠道黏膜相关淋巴组织结外边缘区B细胞淋巴瘤（MALT淋巴瘤）患者临床特征及预后情况。方法回顾性分析90例原发胃肠道MALT淋巴瘤患者资料，对患者临床特征和相关预后因素进行分析。结果90例患者中胃内起病者78例，非胃内起病者12例。国际预后指数（IPI）评分0~2分者80例，3~5分者10例。与胃内起病者比较，非胃内起病者多为IPI 3~5分的高危患者（7.7%对33.3%，P=0.025）、幽门螺旋杆菌（Hp）感染率显著降低（50.0%对87.2%，P<0.01）。IPI评分0~2分的低危患者可选择抗Hp治疗、手术、放疗及化疗等治疗，其中化疗可提高患者无进展生存（PFS）率。接受化疗的高危患者3年总生存（OS）率达100.0%。单因素分析结果显示，ECOG评分（P=0.006）、Musshoff分期（P=0.008）、IPI评分（P=0.000）、LDH水平（P=0.019）和是否接受化疗（P=0.026）是影响患者PFS率的相关因素。多因素分析结果显示IPI评分（3~5分）（OR=8.325，95%CI 3.171~21.853，P= 0.000）和是否接受化疗（OR=0.319，95% CI 0.121~0.838，P=0.020）是影响患者PFS率的独立预后因素，ECOG评分（≥2分）是影响患者OS率的独立预后因素（OR=5.092，95% CI1.005~25.788，P=0.049）。结论原发胃肠道MALT淋巴瘤是一种低度恶性的淋巴瘤，以低危患者多见，多数患者可获得长期生存。低危患者可选择放疗或抗Hp治疗作为起始治疗方案，高危患者应选择化疗。
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
